LSTA
Price
$3.00
Change
+$0.06 (+2.04%)
Updated
Oct 4 closing price
33 days until earnings call
NTLA
Price
$17.99
Change
+$0.34 (+1.93%)
Updated
Oct 4 closing price
26 days until earnings call
Ad is loading...

LSTA vs NTLA

Header iconLSTA vs NTLA Comparison
Open Charts LSTA vs NTLABanner chart's image
Lisata Therapeutics
Price$3.00
Change+$0.06 (+2.04%)
Volume$2.23K
CapitalizationN/A
Intellia Therapeutics
Price$17.99
Change+$0.34 (+1.93%)
Volume$1.85M
CapitalizationN/A
View a ticker or compare two or three
LSTA vs NTLA Comparison Chart
Loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
LSTA vs. NTLA commentary
Oct 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSTA is a Hold and NTLA is a Sell.

COMPARISON
Comparison
Oct 05, 2024
Stock price -- (LSTA: $3.00 vs. NTLA: $17.99)
Brand notoriety: LSTA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSTA: 20% vs. NTLA: 136%
Market capitalization -- LSTA: $24.71M vs. NTLA: $2.13B
LSTA [@Biotechnology] is valued at $24.71M. NTLA’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSTA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • LSTA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, LSTA is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSTA’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • LSTA’s TA Score: 3 bullish, 6 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than LSTA.

Price Growth

LSTA (@Biotechnology) experienced а +3.14% price change this week, while NTLA (@Biotechnology) price change was -14.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

LSTA is expected to report earnings on Nov 07, 2024.

NTLA is expected to report earnings on Oct 31, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.13B) has a higher market cap than LSTA($24.7M). LSTA YTD gains are higher at: 9.941 vs. NTLA (-40.997). LSTA has higher annual earnings (EBITDA): -23.93M vs. NTLA (-514.18M). NTLA has more cash in the bank: 691M vs. LSTA (38.3M). LSTA has less debt than NTLA: LSTA (176K) vs NTLA (106M). NTLA has higher revenues than LSTA: NTLA (46M) vs LSTA (0).
LSTANTLALSTA / NTLA
Capitalization24.7M2.13B1%
EBITDA-23.93M-514.18M5%
Gain YTD9.941-40.997-24%
P/E RatioN/AN/A-
Revenue046M-
Total Cash38.3M691M6%
Total Debt176K106M0%
FUNDAMENTALS RATINGS
LSTA vs NTLA: Fundamental Ratings
LSTA
NTLA
OUTLOOK RATING
1..100
6859
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5487
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (15) in the null industry is in the same range as NTLA (42) in the Biotechnology industry. This means that LSTA’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that NTLA’s stock grew similarly to LSTA’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as LSTA (96) in the null industry. This means that NTLA’s stock grew similarly to LSTA’s over the last 12 months.

LSTA's Price Growth Rating (54) in the null industry is somewhat better than the same rating for NTLA (87) in the Biotechnology industry. This means that LSTA’s stock grew somewhat faster than NTLA’s over the last 12 months.

LSTA's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that LSTA’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LSTANTLA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVIRX35.710.18
+0.51%
Columbia Dividend Income Adv
FUGAX47.440.14
+0.29%
Fidelity Advisor Utilities A
PRDAX11.85N/A
N/A
Principal Diversified Real Asset A
SGARX30.41N/A
N/A
Virtus SGA Global Growth R6
SOIAX9.45-0.03
-0.32%
Spirit of America Real Estate Inc&Gr Ins

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and ARWR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and ARWR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+2.09%
ARWR - LSTA
31%
Poorly correlated
-0.16%
PRME - LSTA
30%
Poorly correlated
+2.93%
NTLA - LSTA
30%
Poorly correlated
+1.93%
ABCL - LSTA
27%
Poorly correlated
+0.81%
KROS - LSTA
27%
Poorly correlated
+1.60%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with EDIT. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+1.93%
EDIT - NTLA
75%
Closely correlated
+5.63%
BEAM - NTLA
75%
Closely correlated
+2.05%
CRSP - NTLA
72%
Closely correlated
+1.05%
VCYT - NTLA
69%
Closely correlated
-0.39%
PRME - NTLA
67%
Closely correlated
+2.93%
More